In chronic myeloproliferative disorders with Bcr-Abl negativity, the JAK2 gene mutation is the most common mutation (accounting for 95% of PV cases, 60% of ET cases, and 50% of PMF cases). This evidence concerns the gene JAK2 and myeloproliferative neoplasm.